SPRAVATO® is the first new drug approved for depression by the Federal Drug Administration (FDA) in decades. SPRAVATO® is especially designed for those suffering from Treatment Resistant Depression (TRD). If you are currently diagnosed with depression and have not responded well to at least two different oral antidepressants, you may qualify for SPRAVATO®.
SPRAVATO® is derived from ketamine, a drug that has been used in hospitals as an anesthetic since the 1970s. Its help in alleviating symptoms of depression is a more recent discovery. SPRAVATO® nasal spray for depression is unique in that